Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Besifovir dipivoxil maleate (BSV), an acyclic nucleotide phosphonate, shows potent antiviral activity against hepatitis B virus. Our previous 48-week trial revealed that BSV has comparable antiviral efficacy to tenofovir disoproxil fumarate (TDF) and better safety profiles in terms of improved renal and bone safety. This extension study evaluated the prolonged efficacy and safety of BSV in treatment-naive chronic hepatitis B patients. Methods: Patients continued to participate in an open-label BSV study after an initial 48-week double-blind comparison of BSV and TDF treatment. The antiviral efficacy and drug safety was evaluated up to 192 weeks in two groups: patients continuing BSV treatment (BSV-BSV) and patients switching from TDF to BSV after 48 weeks (TDF-BSV). Results: Among 197 patients receiving randomized treatments, 170 (86%) entered the open-label phase and 152 (77%) entered the 192-week extension study. Virological response rates over 192 weeks were 92.50% and 93.06% in the BSV-BSV and TDF-BSV groups, respectively (P=0.90). Hepatitis B envelop antigen seroconversion and alanine aminotransferase normalization rates were similar between the groups (P=0.75 and P=0.36, respectively). There were no drug-resistant mutations to BSV. Bone mineral density and renal function were well preserved in the BSV-BSV group, whereas these initially worsened then recovered after switching therapy in the TDF-BSV group. Conclusions: BSV maintained potent antiviral efficacy after 192 weeks and showed no evidence of drug resistance. BSV was safe, well tolerated, and effective in patients who switched from TDF to BSV. Trial Registration Number: NCT01937806 (date: 10 Sep 2013).
Abstract
Background/Aims: Besifovir dipivoxil maleate (BSV), an acyclic nucleotide phosphonate, shows potent antiviral activity against hepatitis B virus. Our previous 48-week trial revealed that BSV has comparable antiviral efficacy to tenofovir disoproxil fumarate (TDF) and better safety profiles in terms of improved renal and bone safety. This extension study evaluated the prolonged efficacy and safety of BSV in treatment-naive chronic hepatitis B patients. Methods: Patients continued to participate in an open-label BSV study after an initial 48-week double-blind comparison of BSV and TDF treatment. The antiviral efficacy and drug safety was evaluated up to 192 weeks in two groups: patients continuing BSV treatment (BSV-BSV) and patients switching from TDF to BSV after 48 weeks (TDF-BSV). Results: Among 197 patients receiving randomized treatments, 170 (86%) entered the open-label phase and 152 (77%) entered the 192-week extension study. Virological response rates over 192 weeks were 92.50% and 93.06% in the BSV-BSV and TDF-BSV groups, respectively (P=0.90). Hepatitis B envelop antigen seroconversion and alanine aminotransferase normalization rates were similar between the groups (P=0.75 and P=0.36, respectively). There were no drug-resistant mutations to BSV. Bone mineral density and renal function were well preserved in the BSV-BSV group, whereas these initially worsened then recovered after switching therapy in the TDF-BSV group. Conclusions: BSV maintained potent antiviral efficacy after 192 weeks and showed no evidence of drug resistance. BSV was safe, well tolerated, and effective in patients who switched from TDF to BSV. Trial Registration Number: NCT01937806 (date: 10 Sep 2013).
참고문헌 (38)
- Schweitzer A, "Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013", Lancet, 386, pp.1546~1555 (2015)
- Wong GL, "Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis", Hepatology, 58, pp.1537~1547 (2013)
- Chevaliez S, "Longterm hepatitis B surface antigen (HBsAg) kinetics during nucleoside", nucleotide analogue therapy: finite treatment duration unlikely, 2013, pp.58, 676~683
- Seto WK, "Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study", Gut, 64, pp.667~672 (2015)
- Liaw YF, "Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study", Hepatology, 13, pp.627~631 (1991)
- European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 25(2), pp.93~159 (2019), 대한간학회
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- Marcellin P, "Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection", Liver Int, 39, pp.1868~1875 (2019)
- 임영석, "Management of Antiviral Resistance in Chronic Hepatitis B", Gut and Liver, 11(2), pp.189~195 (2017), 거트앤리버 소화기연관학회협의회
- Lilian Yan Liang, "Unmet need in chronic hepatitis B management", Clinical and Molecular Hepatology, 25(2), pp.172~180 (2019), 대한간학회
- Ahn SH, "Efficacy and safety of besifovir dipivoxil maleate compared with tenofovir disoproxil fumarate in treatment of chronic hepatitis B virus infection", Clin Gastroenterol Hepatol, 17, pp.1850~1859.e4 (2019)
- Yim HJ, "Besifovir dipivoxil maleate 144-week treatment of chronic hepatitis B: an open-label extensional study of a phase 3 trial", Am J Gastroenterol, 115, pp.1217~1225 (2020)
- Kwon SY, "Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients", J Virol, 84, pp.4494~4503 (2010)
- Park ES, "Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients", J Hepatol, 70, pp.1093~1102 (2019)
- Gordon SC, "Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load", Hepatology, 58, pp.505~513 (2013)
- Ridruejo E, "Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice", Ann Hepatol, 13, pp.327~336 (2014)
- Chen CF, "Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma", Gastroenterology, 141, pp.240~1248 (2011)
- Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study", Lancet, 381, pp.468~475 (2013)
- Liang X, "Longterm efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results", Hepatol Int, 13, pp.260~269 (2019)
- Perrillo RP, "Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B", Hepatology, 36, pp.186~194 (2002)
- Zeuzem S, "Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B", J Hepatol, 51, pp.11~20 (2009)
- Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)
- Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", N Engl J Med, 351, pp.1521~1531 (2004)
- Papatheodoridis GV, "Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine", Hepatology, 42, pp.121~129 (2005)
- Lim YS, "Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial", Hepatology, 66, pp.772~783 (2017)
- Heathcote EJ, "Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B", Gastroenterology, 140, pp.132~143 (2011)
- Gill US, "Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?", J Infect Dis, 211, pp.374~382 (2015)
- Young Youn Cho, "Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B", Gut and Liver, 14(2), pp.225~231 (2020), 거트앤리버 소화기연관학회협의회
- Rodríguez-Nóvoa S, "Altered underlying renal tubular function in patients with chronic hepatitis B receiving nucleos(t)ide analogs in a real-world setting: the MENTE study", J Clin Gastroenterol, 50, pp.779~789 (2016)
- Lai CL, "Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B", Gut, 63, pp.996~1004 (2014)
- Yuen MF, "Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study", J Hepatol, 62, pp.526~532 (2015)
- Fong TL, "Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide", J Viral Hepat, 26, pp.561~567 (2019)
- Cid-Silva P, "Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine", Basic Clin Pharmacol Toxicol, 124, pp.479~490 (2019)
- "Changes in lipids after a direct switching from TDF to TAF"[URL]
- Ewers E, "Changes in lipid profiles for patients to tenofovir alafenamide (TAF)-containing regimens: perspectives from a military HIV-positive cohort", Open Forum Infect Dis, 5, pp.S665~ (2018)
- Chan HL, "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial", Lancet Gastroenterol Hepatol, 1, pp.185~195 (2016)
- Buti M, "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial", Lancet Gastroenterol Hepatol, 1, pp.196~206 (2016)